From the Journals

More evidence links increased BMI to higher multiple myeloma risk


 

FROM BRITISH JOURNAL OF CANCER

A high body mass index in both early and later adulthood increases the risk for developing multiple myeloma (MM), according to a prospective analysis.

“This association did not significantly differ by gender but was nonetheless slightly stronger in men,” wrote Catherine R. Marinac, PhD, of the Dana-Farber Cancer Institute, Boston, and her colleagues. “MM risk was significantly positively associated with weight change and suggestive of a positive association for change in BMI since young adulthood. In contrast, we did not observe statistically significant associations of cumulative average physical activity or walking with MM risk.”

Dr. Marinac and her associates analyzed participants from the Nurses’ Health Study (NHS), the Health Professionals Follow-Up Study (HPFS), and the Women’s Health Study (WHS) with a pooled total of 575 MM cases and more than 5 million person-years of follow-up. From all of those databases, a combined baseline total of 49,374 men and 153,260 women were included in the analyses. Participants in all three of the cohorts were predominately white.

Each participant was required to report height and weight on a baseline questionnaire and updated weights on subsequent questionnaires. Using that height and weight information, the researchers calculated BMI. Physical activity also was reported using questionnaires, beginning in 1986 in the HPFS and NHS groups and at baseline for WHS, with all groups providing updates every 2-4 years. The researchers used the physical activity information to calculate the total metabolic equivalent (MET) hours of all activity and of walking per week.

Pages

Recommended Reading

FDA alert: pembrolizumab ups mortality risk in multiple myeloma
Federal Practitioner
New antibodies, drugs for refractory and relapsed myeloma are effective in patients over 65
Federal Practitioner
Tailored approaches to relapsed/recalcitrant myeloma found within NCCN guidelines
Federal Practitioner
Treatment and Management of Multiple Myeloma (FULL)
Federal Practitioner
Cyclophosphamide after transplant reduced GVHD in myeloma patients
Federal Practitioner
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
Federal Practitioner
Anti-BCMA CAR T-cell therapy being fast tracked at FDA
Federal Practitioner
Continue to opt for HDT/ASCT for multiple myeloma
Federal Practitioner
Meningococcal Arthritis Masking as Possible Myeloma
Federal Practitioner
In myeloma, third ASCT is a viable option
Federal Practitioner